Dose Response to Recombinant Factor VIIa When Administered for Bleed



Status:Completed
Conditions:Healthy Studies, Hematology
Therapuetic Areas:Hematology, Other
Healthy:No
Age Range:18 - 60
Updated:1/13/2017
Start Date:June 2004
End Date:November 2004

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Recombinant Activated Factor VII (rFVIIa/NovoSeven) Dose Response Trial in Healthy Volunteers: A Double-Blind, Placebo-Controlled, Cross-over, Dose-Escalation Trial to Investigate the Dose Response to REcombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers

This trial is conducted in the United States of America (USA). The purpose of this trial is
to investigate the dose response to recombinant factor VIIa in healthy volunteers when
administered for bleed.


Inclusion Criteria:

- Ages Eligible for Study: 18 Years - 60 Years

Exclusion Criteria:
We found this trial at
1
site
Novo Nordisk Investigational Site
Overland Park, Kansas 66209
?
mi
from
Overland Park, KS
Click here to add this to my saved trials